Shares of Trovagene Inc. (NASDAQ:TROV) dropped 3.4% during mid-day trading on Thursday . The stock traded as low as $4.86 and last traded at $4.89, with a volume of 241,804 shares changing hands. The stock had previously closed at $5.06.

TROV has been the topic of several recent research reports. Maxim Group initiated coverage on Trovagene in a research report on Wednesday, July 6th. They set a “buy” rating and a $12.00 target price on the stock. Piper Jaffray Cos. set a $4.00 target price on Trovagene and gave the company a “hold” rating in a research report on Friday, August 5th. Zacks Investment Research raised Trovagene from a “sell” rating to a “hold” rating in a research report on Wednesday, July 13th. Cantor Fitzgerald raised Trovagene from a “hold” rating to a “buy” rating and increased their target price for the company from $5.00 to $7.00 in a research report on Monday, August 8th. Finally, Leerink Swann reaffirmed a “hold” rating on shares of Trovagene in a research report on Thursday, May 12th. Five equities research analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. The company has a consensus rating of “Hold” and an average target price of $7.13.

The company has a 50 day moving average price of $5.29 and a 200 day moving average price of $5.00. The stock’s market capitalization is $150.74 million.

Trovagene (NASDAQ:TROV) last announced its earnings results on Thursday, August 4th. The company reported ($0.34) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.31) by $0.03. Equities analysts forecast that Trovagene Inc. will post ($1.33) earnings per share for the current year.

Trovagene, Inc (TrovaGene) is a molecular diagnostic company. The Company focuses on the development and commercialization of a molecular diagnostic technology for use in disease detection and monitoring across a range of medical disciplines. Its primary internal focus is to leverage its cell-free molecular diagnostic platform to facilitate improvements in the field of oncology, while its external focus includes entering into license agreements or collaborations to develop its technology in areas, such as infectious disease, transplant medicine and prenatal genetics.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.